A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Urologic NeoplasmsMetastatic Bladder CancerUrinary Tract Neoplasms
Interventions
DRUG

OGX-427 600 mg

Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.

DRUG

OGX-427 1000 mg

Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.

DRUG

Placebo

Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.

DRUG

Gemcitabine

Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

DRUG

Cisplatin

Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

DRUG

Carboplatin

Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Trial Locations (55)

Unknown

City of Hope National Medical Center, Duarte

Cedars-Sinai Medical Center, Los Angeles

University of California Los Angeles, Los Angeles

USC Norris Comprehensive Cancer Center, Los Angeles

Radiological Associates of Sacramento, Sacramento

Yale University, New Haven

Karmanos Cancer Institute, Detroit

Siteman Cancer Center, Washington University School of Medicine, St Louis

Urology Cancer Center and GU Research Network, Omaha

Monter Cancer Center, Lake Success

Columbia University Medical Center, New York

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

Texas Oncology, P.A., Dallas

Seattle Cancer Care Alliance, Seattle

Tom Baker Cancer Center, Calgary

Cross Cancer Center, Edmonton

British Columbia Cancer Agency, Vancouver

Juravinski Cancer Centre, Hamilton

R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health, Oshawa

Princess Margaret Hospital, Toronto

CHUM-Hospital Notre Dame, Montreal

Centre Hospitalier Régional et Universitaire - Hôpital, Bretonneau Tours

Institute Jean Godinot, Reims

Centre Hospitalier Universitaire de Rouen, Rouen

Centre Paul Papin, Angers

Medicale Centre René Gauducheau, Saint-Herblain

Institut Paoli Calmettes, Marseille

Centre Antoine Lacassagne, Nice

Centre Hospitalier Universitaire, Institut Gustave Roussy, Villejuif

Universitätsklinikum Heidelberg, Heidelberg

Klinikum Rechts der Isar der Technischen Universität, München

Johann-Wolfgang-Goethe-Universität Frankfurt, Frankfurt am Main

Medizinische Hochschule Hannover, Hanover

Universitätsklinikum des Saarlandes, Homburg

Universitätsklinikum Dresden, Dresden

Universitätsklinikum Magdeburg A.ö.R., Magdeburg

Universitätsklinikum Jena, Jena

Universitätsklinikum Mainz, Mainz

Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena

Fondazione IRCCS Policlinico San Matteo Pavia, Pavia

Unità Operativa di Oncologia Medica, Roma

Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz

Akademicki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw

NZOZ Europejskie Centrum Zdrowia Otwock, Otwock

Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Warsaw

Uniwersyteckie Centrum Kliniczne, Gdansk

Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn

Hospital Santa Creu i Sant Pau, Barcelona

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Clinic I Provincial de Barcelona, Barcelona

Hospital del Mar, Barcelona

Hospital Vall d´Hebrón, Barcelona

Institut Català D'Oncologia, Hospital Duran i Reynals, Madrid

Instituto Valenciano de Oncología-Fundación (IVO-FINCIVO), Valencia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

Achieve Life Sciences

INDUSTRY